IACP Sends Letter to Senate Committee on Health, Education, Labor and Pensions (HELP)
On March 20, 2013, the International Academy of Compounding Pharmacists (IACP), provided comments and insights, as requested by the Senate Health, Education, Labor and Pension Committee (HELP), into a conceptual model proposed by the Food and Drug Administration (FDA), intended to address the safety of compounded medications and to clarify the FDA's authority in this area.
IACP's comments were developed based upon input obtained from February's IACP Member Survey and from our IACP Board and Executive Committee.
IACP appreciates the opportunity to work with the HELP Committee to ensure that a tragedy like the one that occurred last year, when compounded preparations dispensed by a Massachusetts licensed pharmacy caused an outbreak of fungal meningitis, never happens again.
Please note - No compounding legislation has been introduced either in the Senate or the House at the present time. While IACP continues to work with legislators and their staff on concepts and issues that may be included in a future bill -- and in this case is addressing the very nebulous concept circulated by the FDA -- it's important to understand that much is in discussion which may or may not ever move forward. All IACP members should continue to read our Academy's communications so that if and when it is necessary to reach out to your own legislative delegation, you'll be ready.
Click here to view IACP's letter to Chairman Tom Harkin and Ranking Member Lamar Alexander of the Senate Health, Education, Labor and Pension Committee.
Click here to view IACP's Recommendations for State-Based Legislative and Regulatory Initiatives.
What to Do Should you Receive Media Calls
If you receive calls from the media, IACP encourages you to direct press inquiries to your Academy's PR Firm, David Ball, Ball Consulting Group. This media assistance is part of your benefits as an IACP member.
David Ball, Ball Consulting Group, LLC
Please email IACP at firstname.lastname@example.org with any questions.